2015 American Transplant Congress
Sofosbuvir-Based Therapy for Hepatitis C Recurrence Post Liver Transplantation
Introduction:Sofosbuvir is approved to treat HCV infection in all genotypes with sustained virological response 12 weeks after completion of therapy (SVR12)rates of up to 100%.…2015 American Transplant Congress
End of Treatment Liver Biopsy With Sofosbuvir: Histologic Changes Suggestive of Hepatitis C Activity in Liver Transplant Recipients With Achieved SVR
Background: Interferon (IFN) free HCV regimens are associated with better tolerability and efficacy. The majority of studies report biochemical and virological response; however limited information…2015 American Transplant Congress
Sofosbuvir Therapy in Early and Late Post Liver Transplant Setting: A Single Center Experience
Background: Hepatitis C (HCV) treatment has entered a new phase of excitement with new oral therapies. Here we describe our experience of sofosbuvir (SOF) based…2015 American Transplant Congress
Efficacy and Safety of Once-Daily Everolimus With Minimized Once-Daily Tacrolimus After Liver Transplantation
Background: The everolimus (EVR) pharmacokinetic profile allows for its once daily (OD) administration. We tested the efficacy and safety of a combination schedule of OD-EVR…2015 American Transplant Congress
Forty-Seven Consecutive Simultaneous Liver-Kidney Transplants With Steroid Free Immunosuppression After Rabbit Antithymocyte Globulin Induction
Introduction: Utilization of rabbit antithymocyte globulin (RATG) induction as part of a steroid free immunosuppression protocol in orthotopic liver transplantation has gained wide acceptance in…2015 American Transplant Congress
The Effect of Preformed and De Novo Donor-Specific Antibodies (DSA) in Acute Rejection (AR) After Liver Transplantation (LTX)
BACKGROUND: The role of preformed and den novo formed DSA in LTX is not fully revealed. The aim of our study was to determine if…2015 American Transplant Congress
Results of ABO Incompatible Liver Transplantation Using a Simplified Protocol at a Single Institution
BackgroundABO incompatible (ABOi) living donor liver transplantation (LDLT) has become a feasible option for patients with end-stage liver disease due to development of various desensitization…2015 American Transplant Congress
Incidence and Impact of De Novo Donor-Specific Anti-HLA Antibodies in ABO-Compatible Liver-Transplant Recipients
Background: The incidence and consequences of de novo donor-specific anti-HLA antibodies (DSAs) after liver transplantation (LT) are not well known. Thus, we investigated the incidence,…2015 American Transplant Congress
Renal Function Following Basiliximab Induction in Liver Transplant Recipients
Washington University School of Medicine, St. Louis.
Purpose: Reports of the use of antibody induction to delay the start of calcineurin inhibitor therapy postoperatively in patients with renal insufficiency at the time…2015 American Transplant Congress
Effects of Early Everolimus Use for Immunosuppression in Living Donor Liver Transplant Recipients- An Analysis of 215 Sequential Patients
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan.
Purpose:In our previously published study, we concluded the safety of everolimus (EVR) in early stage after living donor liver transplantation (LDLT). In this large scale…
American Transplant Congress abstracts